Viatris Inc (VTRS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $23.87B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viatris Inc (VTRS) Earnings: Report Dates and Results
Viatris (VTRS) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Viatris reported EPS of $0.71, above the $0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VTRS has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.8% above the $0.57 reported for the quarter ended Dec 31, 2025.
VTRS Earnings Call
The latest VTRS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, VTRS beat 29, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $3.75B, down 0.3% from $3.76B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.71 | $0.64 | $0.62 - $0.66 | +10.94% | Beat | +6.0% | 10 | 1 up, 2 down | Nov 5, 2026 | $3.75B |
| Jun 30, 2026 | $0.69 | $0.62 | $0.57 - $0.62 | +11.29% | Beat | +11.3% | 8 | 1 up, 2 down | Aug 6, 2026 | $3.76B |
| Mar 31, 2026 | $0.59 | $0.50 | $0.48 - $0.55 | +18.00% | Beat | +18.0% | 8 | 1 up, 2 down | May 7, 2026 | $3.52B |
| Dec 31, 2025 | $0.57 | $0.52 | $0.51 - $0.59 | +9.62% | Beat | +5.6% | 8 | 0 up, 2 down | Feb 26, 2026 | $3.70B |
| Sep 30, 2025 | $0.67 | $0.62 | $0.60 - $0.64 | +8.06% | Beat | -10.7% | 7 | 1 up, 1 down | Nov 6, 2025 | $3.76B |
| Jun 30, 2025 | $0.62 | $0.56 | $0.53 - $0.58 | +10.71% | Beat | -10.1% | 5 | 1 up, 0 down | Aug 7, 2025 | $3.58B |
| Mar 31, 2025 | $0.50 | $0.49 | $0.45 - $0.52 | +2.04% | Beat | -25.4% | 4 | 0 up, 1 down | May 8, 2025 | $3.25B |
| Dec 31, 2024 | $0.54 | $0.57 | $0.54 - $0.61 | -5.59% | Miss | -12.9% | 6 | 0 up, 1 down | Feb 27, 2025 | $3.53B |
| Sep 30, 2024 | $0.75 | $0.68 | $0.64 - $0.71 | +10.29% | Beat | -5.1% | 6 | 0 up, 0 down | Nov 7, 2024 | $3.75B |
| Jun 30, 2024 | $0.69 | $0.68 | $0.65 - $0.70 | +1.47% | Beat | -8.0% | 6 | 0 up, 0 down | Aug 8, 2024 | $3.80B |
| Mar 31, 2024 | $0.67 | $0.67 | $0.64 - $0.70 | 0.00% | In line | -13.0% | 6 | 0 up, 0 down | May 9, 2024 | $3.66B |
| Dec 31, 2023 | $0.62 | $0.65 | $0.57 - $0.70 | -4.62% | Miss | -7.5% | 6 | 0 up, 0 down | Feb 28, 2024 | $3.84B |
| Sep 30, 2023 | $0.79 | $0.74 | $0.67 - $0.79 | +6.76% | Beat | -9.2% | 7 | 0 up, 0 down | Nov 7, 2023 | $3.94B |
| Jun 30, 2023 | $0.75 | $0.71 | $0.68 - $0.75 | +5.63% | Beat | -14.8% | 7 | 1 up, 0 down | Aug 7, 2023 | $3.92B |
| Mar 31, 2023 | $0.77 | $0.70 | $0.65 - $0.72 | +10.00% | Beat | -17.2% | 8 | 0 up, 0 down | May 8, 2023 | $3.73B |
| Dec 31, 2022 | $0.67 | $0.72 | $0.55 - $0.94 | -6.94% | Miss | -16.3% | 11 | 1 up, 0 down | Feb 27, 2023 | $3.88B |
| Sep 30, 2022 | $0.87 | $0.84 | $0.79 - $0.93 | +3.57% | Beat | -12.1% | 10 | 0 up, 1 down | Nov 7, 2022 | $4.08B |
| Jun 30, 2022 | $0.88 | $0.82 | $0.74 - $0.88 | +7.32% | Beat | -10.2% | 9 | 0 up, 1 down | Aug 8, 2022 | $4.12B |
| Mar 31, 2022 | $0.93 | $0.83 | $0.77 - $0.88 | +12.05% | Beat | +1.1% | 10 | 0 up, 0 down | May 9, 2022 | $4.19B |
| Dec 31, 2021 | $0.80 | $0.83 | $0.78 - $0.98 | -3.61% | Miss | -25.9% | 11 | N/A | Feb 28, 2022 | $4.34B |
| Sep 30, 2021 | $0.99 | $0.88 | $0.82 - $0.96 | +12.50% | Beat | -24.4% | 10 | 5 up, 0 down | Nov 8, 2021 | $4.54B |
| Jun 30, 2021 | $0.98 | $0.88 | $0.77 - $0.95 | +11.36% | Beat | -11.7% | 12 | N/A | Aug 9, 2021 | $4.58B |
| Mar 31, 2021 | $0.92 | $0.80 | $0.70 - $0.89 | +15.00% | Beat | +2.2% | 12 | N/A | May 10, 2021 | $4.43B |
| Dec 31, 2020 | $1.08 | $1.24 | $0.88 - $1.79 | -12.90% | Miss | -22.9% | 13 | N/A | Mar 1, 2021 | $3.62B |
| Sep 30, 2020 | $1.31 | $1.16 | N/A | +12.93% | Beat | +12.0% | N/A | N/A | Nov 6, 2020 | $2.97B |
| Jun 30, 2020 | $1.11 | $0.98 | N/A | +13.27% | Beat | +7.8% | N/A | N/A | Aug 6, 2020 | $2.73B |
| Mar 31, 2020 | $0.90 | $0.87 | N/A | +3.45% | Beat | +9.8% | N/A | N/A | May 11, 2020 | $2.62B |
| Dec 31, 2019 | $1.40 | $1.28 | N/A | +9.38% | Beat | +7.7% | N/A | N/A | Feb 27, 2020 | $3.19B |
| Sep 30, 2019 | $1.17 | $1.14 | N/A | +2.63% | Beat | -6.4% | N/A | N/A | Nov 5, 2019 | N/A |
| Jun 30, 2019 | $1.03 | $0.95 | N/A | +8.42% | Beat | -3.7% | N/A | N/A | Jul 29, 2019 | N/A |
| Mar 31, 2019 | $0.82 | $0.79 | N/A | +3.80% | Beat | -14.6% | N/A | N/A | May 7, 2019 | $2.50B |
| Dec 31, 2018 | $1.30 | $1.36 | N/A | -4.41% | Miss | -9.1% | N/A | N/A | Feb 26, 2019 | $3.08B |
| Sep 30, 2018 | $1.25 | $1.19 | N/A | +5.04% | Beat | +13.6% | N/A | N/A | Nov 5, 2018 | $2.86B |
| Jun 30, 2018 | $1.07 | $1.22 | N/A | -12.30% | Miss | -2.7% | N/A | N/A | Aug 8, 2018 | $2.81B |
| Mar 31, 2018 | $0.96 | $0.96 | N/A | 0.00% | In line | +3.2% | N/A | N/A | May 9, 2018 | $2.68B |
| Dec 31, 2017 | $1.43 | $1.41 | N/A | +1.42% | Beat | -8.9% | N/A | N/A | Feb 28, 2018 | $3.24B |
| Sep 30, 2017 | $1.10 | $1.20 | N/A | -8.33% | Miss | -20.3% | N/A | N/A | Nov 6, 2017 | $2.99B |
| Jun 30, 2017 | $1.10 | $1.16 | N/A | -5.17% | Miss | -5.2% | N/A | N/A | Aug 9, 2017 | $2.96B |
| Mar 31, 2017 | $0.93 | $0.92 | N/A | +1.09% | Beat | +22.4% | N/A | N/A | May 10, 2017 | $2.72B |
| Dec 31, 2016 | $1.57 | $1.42 | N/A | +10.56% | Beat | +28.7% | N/A | N/A | Mar 1, 2017 | $3.27B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.36, down 10.9% from the year before. It was $4.87 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.36 | -10.9% |
| Dec 31, 2024 | $2.65 | -9.6% |
| Dec 31, 2023 | $2.93 | -12.5% |
| Dec 31, 2022 | $3.35 | -9.2% |
| Dec 31, 2021 | $3.69 | -16.1% |
| Dec 31, 2020 | $4.40 | N/A |
| Dec 31, 2019 | $4.42 | -3.5% |
| Dec 31, 2018 | $4.58 | N/A |
| Dec 31, 2017 | $4.56 | -6.4% |
| Dec 31, 2016 | $4.87 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,035 | 15 | |
| 2026Q2 | Jun 30, 2026 | 8,284 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,338 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,809 | 15 | |
| 2025Q3 | Sep 30, 2025 | 5,689 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,828 | 11 | |
| 2025Q1 | Mar 31, 2025 | 5,887 | 11 | |
| 2024Q4 | Dec 31, 2024 | 7,649 | 12 |
2026Q3 Earnings Call
Opening remarks
William Szablewski Head of Capital Markets Good morning, everyone. Welcome to our Q3 2026 earnings call. With us today is our CEO, Scott Smith; Interim CFO, Paul Campbell; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to the most directly comparable GAAP measures. When discussing 2026 actual or reported results, we will be making certain comparisons to 2025 actual or reported results on an operational basis, which excludes the impact of foreign currency rates. When comparing our 2026 actual reported results to our expectations, we are making comparisons to our 2026 financial guidance. With that, I'll hand the call over to our CEO, Scott Smith.
Scott Smith CEO Good morning, everyone. We're pleased with our strong third quarter performance, which reflects continued momentum across our businesses. As we've been saying, we believe we've entered a new phase of sustained growth for Viatris. The disciplined execution of the strategy we outlined earlier this year is translating into results. During the third quarter, we delivered total revenues of $3.75 billion, adjusted EBITDA of $1.2 billion and adjusted EPS of $0.71 per share. Through the first 9 months of the year, total revenues grew 2%, adjusted EBITDA grew 6% and adjusted EPS grew 8% operationally compared to the prior year, demonstrating continued progress toward our long-term financial targets. Given our performance and expectations for continued momentum in the fourth quarter, we are narrowing our financial guidance ranges and once again raising the midpoint for all key financial metrics. Paul will provide more details shortly. Now let me walk through a few highlights for the quarter. Our base business continues to deliver solid results, reflecting the strength and durability of our portfolio. We're pleased with our performance in North America and Greater China, where we continue to see meaningful growth. In North America, growth is accelerating as our portfolio mix shifts toward more durable, higher-margin products and complex generics, supported by strong demand for our estradiol patches and new product revenue from our recent injectable launches. We are pleased to have launched Gwyn Lo, our low-dose contraceptive patch in the U.S. in October. In Greater China, growth continues to be driven by strong demand for our cardiovascular portfolio and the strength of our established brands.
Frequently Asked Questions About VTRS
When is Viatris's next earnings date?
Viatris's next earnings report is expected for Feb 24, 2027.
Did VTRS beat earnings estimates last quarter?
Yes. Viatris reported EPS of $0.71 for the quarter ended Sep 30, 2026, above the $0.64 estimate, a 10.94% surprise.
What EPS do analysts expect from VTRS next quarter?
The consensus EPS estimate for Viatris for the quarter ending Dec 31, 2026 is $0.62 from 12 analysts, with estimates from $0.56 to $0.66.
How often does VTRS beat earnings estimates?
Viatris beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.13%.
VTRS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts